About Cantabio Pharmaceuticals
Cantabio Pharmaceuticals is a pre-clinical drug development company developing novel therapeutics for neurodegenerative diseases and metabolic diseases, such as type 2 diabetes, by addressing the root causes of these diseases - biochemical stress in the form of protein misfolding and aggregation, oxidative and glyoxal stress. The company's pipeline has 4 main programs, developing small molecule disease modifying drugs targeting both well-established targets such as tau for Alzheimer’s and other tauopathies such as CTE, and a novel target in DJ-1, a multifunctional defensive protein with a number of key roles in defending cells from biochemical stress. DJ-1 is genetically linked to Parkinson’s disease, has been shown to be involved in the pathology of Alzheimer's and is implicated in a number of other diseases including type 2 diabetes, male infertility and conditions related to ageing. Cantabio’s work in targeting intrinsically disordered proteins was featured in a World Economic Forum report as one of the “top 10 emerging world-changing technologies for 2019” with Cantabio being one of few companies capable of therapeutically targeting this special class of promising drug targets for Alzheimer’s and cancer.
The company was founded in Palo Alto, California in 2009 as Gardedam Therapeutics in order to pursue novel drug discovery research to develop pharmacological chaperones targeting a number of proteins linked to Alzheimer’s and Parkinson’s disease. The companies’ R&D was strengthened with an initial partnership with Dr. C. Rochet at Purdue University and Novalix and Gardedam was awarded two separate grants in collaboration with Dr. Rochet in 2010 and 2013 by the Michael J. Fox Foundation in support of its DJ-1 therapeutic project. Cantabio Pharmaceuticals, Inc. was established through the merger of Gardedam Therapeutics with Cantabio Pharmaceuticals in November of 2015.
Cantabio Pharmaceuticals conducts in-house R&D on critical elements of its drug discovery pipeline, while forming strategic alliances around novel technologies and outsourcing generic research activities to established contract research organizations. Cantabio has operations in Palo Alto (USA) and Budapest (Hungary) where the company carries out in-house R&D in modern laboratory facilities. This balance of out-sourced and in-house R&D capabilities has enabled Cantabio to maintain high levels of operational efficiency and highly effective use of funds, while ensuring development and operation of key technologies in-house.
The Neurodegenerative Disease market is huge (over $17 billion) and is in continuous growth as human lifespan increases and the baby boomer generation grows older.
Our leadership team first came together while studying for the Executive MBA at the Judge Business School, University of Cambridge. Each member boasts impressive experience, coupling successful scientific, academic and business achievements and wide ranging industry experience.